



Abbott India Limited  
Godrej BKC, Plot C-68, "G" Block,  
15-16th Floor, Bandra-Kurla Complex,  
Near MCA Club, Bandra (E),  
Mumbai - 400 051. India

Registered Office:  
3, Corporate Park,  
Sion Trombay Road,  
Mumbai - 400 071. India

Tel : (91-22) 5046 1000/2000  
Fax : (91-22) 5016 9400  
E-mail : webmasterindia@abbott.com  
Website : www.abbott.co.in  
CIN : L24239MH1944PLC007330

**STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022**

(Rs. in Crores except earnings per share)

Particulars	Quarter ended			Nine months ended		Year ended
	December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1 Income</b>						
(a) Revenue from operations	1,326.48	1,379.48	1,224.36	4,010.33	3,664.25	4,919.27
(b) Other income	39.94	33.53	18.74	99.83	56.16	77.21
<b>Total Income</b>	<b>1,366.42</b>	<b>1,413.01</b>	<b>1,243.10</b>	<b>4,110.16</b>	<b>3,720.41</b>	<b>4,996.48</b>
<b>2 Expenses</b>						
(a) Cost of materials consumed	134.26	137.38	108.07	429.72	373.08	495.46
(b) Purchases of stock-in-trade	462.83	625.88	509.58	1,677.68	1,545.29	2,184.03
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	147.77	(11.14)	31.06	107.60	62.83	(22.28)
(d) Employee benefits expense	135.24	149.56	141.62	436.89	443.98	579.46
(e) Finance costs	3.79	3.97	4.41	11.98	13.96	19.10
(f) Depreciation and amortisation expense	17.81	17.47	16.74	52.63	48.67	66.10
(g) Other expenses	129.89	134.50	164.97	428.25	445.17	594.88
<b>Total Expenses</b>	<b>1,031.59</b>	<b>1,057.62</b>	<b>976.45</b>	<b>3,144.75</b>	<b>2,932.98</b>	<b>3,916.75</b>
<b>3 Profit before tax (1-2)</b>	<b>334.83</b>	<b>355.39</b>	<b>266.65</b>	<b>965.41</b>	<b>787.43</b>	<b>1,079.73</b>
<b>4 Tax expenses</b>						
(a) Current tax expense	88.99	91.70	68.06	251.46	207.69	276.98
(b) Tax adjustment for earlier years	0.69	-	-	0.69	-	4.18
(c) Deferred tax expense/(credit)	(1.68)	(1.83)	(0.61)	(4.73)	(7.55)	(0.13)
<b>Total Tax Expenses</b>	<b>88.00</b>	<b>89.87</b>	<b>67.45</b>	<b>247.42</b>	<b>200.14</b>	<b>281.03</b>
<b>5 Profit for the period (3-4)</b>	<b>246.83</b>	<b>265.52</b>	<b>199.20</b>	<b>717.99</b>	<b>587.29</b>	<b>798.70</b>
<b>6 Other Comprehensive Income</b>						
Items that will not be reclassified subsequently to Profit or Loss	0.43	0.98	(0.04)	2.38	(5.78)	3.90
Income tax on above	(0.11)	(0.24)	0.01	(0.60)	1.46	(0.98)
<b>Total Other Comprehensive Income, net of tax</b>	<b>0.32</b>	<b>0.74</b>	<b>(0.03)</b>	<b>1.78</b>	<b>(4.32)</b>	<b>2.92</b>
<b>7 Total Comprehensive Income for the period, net of tax (5+6)</b>	<b>247.15</b>	<b>266.26</b>	<b>199.17</b>	<b>719.77</b>	<b>582.97</b>	<b>801.62</b>
<b>8 Paid-up Equity Share Capital</b> (Face Value of Rs.10 per Equity Share)	<b>21.25</b>	<b>21.25</b>	<b>21.25</b>	<b>21.25</b>	<b>21.25</b>	<b>21.25</b>
<b>9 Other Equity</b>	-	-	-	-	-	2,798.54
<b>10 Earnings per equity share - Basic/Diluted</b> (of Rs.10/- each) (not annualised) (5/8)	<b>116.16</b>	<b>124.95</b>	<b>93.74</b>	<b>337.88</b>	<b>276.37</b>	<b>375.86</b>

SIGNED FOR IDENTIFICATION  
BY

✍

S R B C & CO LLP  
MUMBAI

**NOTES :**

- 1 The above financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on February 10, 2023.
- 2 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016.
- 3 The financial results for quarter and nine months ended December 31, 2022 have been subjected to limited review by the statutory auditors of the Company. The Limited Review Report does not contain any qualifications.
- 4 The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.
- 5 Figures for the previous periods have been regrouped/reclassified wherever considered necessary.

**For and on behalf of the Board of Directors of  
Abbott India Limited**

  
**VIVEK V KAMATH**  
Managing Director  
DIN : 06606777

Place : Mumbai  
Date : February 10, 2023

  
**SIGNED FOR IDENTIFICATION**  
By:   
**S R B C & CO LLP**  
**MUMBAI**